The gut microbiome in end-stage lung disease and lung transplantation

Shuyan Zhang,J. Casper Swarte,Ranko Gacesa,Tim J. Knobbe,Daan Kremer,Bernadien H. Jansen,Martin H. de Borst,Hermie J. M. Harmsen,Michiel E. Erasmus,Erik A. M. Verschuuren,Stephan J. L. Bakker,C. Tji Gan,Rinse K. Weersma,Johannes R. Björk,Coby Annema,Stephan J. L. Bakker,Stefan P. Berger,Hans Blokzijl,Frank A. J. A. Bodewes,Marieke T. de Boer,Kevin Damman,Martin H. de Borst,Arjan Diepstra,Gerard Dijkstra,Rianne M. Douwes,Caecilia S. E. Doorenbos,Michele F. Eisenga,Michiel E. Erasmus,C. Tji Gan,Eelko Hak,Bouke G. Hepkema,Frank Klont,Tim J. Knobbe,Daan Kremer,Henri G. D. Leuvenink,Willem S. Lexmond,Vincent E. de Meijer,Hubert G. M. Niesters,Gertrude J. Nieuwenhuis-Moeke,L. Joost van Pelt,Robert A. Pol,Robert J. Porte,Adelta V. Ranchor,Marion J. Siebelink,Riemer J. H. J. A. Slart,J. Casper Swarte,Daan J. Touw,Marius C. van den Heuvel,Coretta van Leer-Buter,Marco van Londen,Erik A. M. Verschuuren,Michel J. Vos,Rinse K. Weersma,Antonio W. Gomes Neto,Jan Stephan F. Sanders,TransplantLines Investigators
DOI: https://doi.org/10.1128/msystems.01312-23
2024-05-08
mSystems
Abstract:ABSTRACT Gut dysbiosis has been associated with impaired outcomes in liver and kidney transplant recipients, but the gut microbiome of lung transplant recipients has not been extensively explored. We assessed the gut microbiome in 64 fecal samples from end-stage lung disease patients before transplantation and 219 samples from lung transplant recipients after transplantation using metagenomic sequencing. To identify dysbiotic microbial signatures, we analyzed 243 fecal samples from age-, sex-, and BMI-matched healthy controls. By unsupervised clustering, we identified five groups of lung transplant recipients using different combinations of immunosuppressants and antibiotics and analyzed them in relation to the gut microbiome. Finally, we investigated the gut microbiome of lung transplant recipients in different chronic lung allograft dysfunction (CLAD) stages and longitudinal gut microbiome changes after transplantation. We found 108 species (58.1%) in end-stage lung disease patients and 139 species (74.7%) in lung transplant recipients that were differentially abundant compared with healthy controls, with several species exhibiting sharp longitudinal increases from before to after transplantation. Different combinations of immunosuppressants and antibiotics were associated with specific gut microbial signatures. We found that the gut microbiome of lung transplant recipients in CLAD stage 0 was more similar to healthy controls compared to those in CLAD stage 1. Finally, the gut microbial diversity of lung transplant recipients remained lower than the average gut microbial diversity of healthy controls up to more than 20 years post-transplantation. Gut dysbiosis, already present before lung transplantation was exacerbated following lung transplantation. IMPORTANCE This study provides extensive insights into the gut microbiome of end-stage lung disease patients and lung transplant recipients, which warrants further investigation before the gut microbiome can be used for microbiome-targeted interventions that could improve the outcome of lung transplantation.
microbiology
What problem does this paper attempt to address?
The paper primarily explores the changes in the gut microbiota of patients with end-stage lung disease (ESLD) and lung transplant recipients (LTR), and analyzes the relationship between these changes and drug treatment, as well as the stages of chronic lung allograft dysfunction (CLAD). The paper attempts to address the following questions: 1. **The extent of changes in the gut microbiota in patients with end-stage lung disease and lung transplant recipients**: The study evaluates the degree of gut microbiota imbalance by comparing the gut microbiota composition between patients with end-stage lung disease and healthy control groups, as well as between lung transplant recipients and healthy control groups. 2. **The impact of different drug treatment regimens on the gut microbiota after lung transplantation**: Through cluster analysis, five different combinations of immunosuppressants and antibiotics were identified, and the study explores whether these different drug combinations are associated with specific gut microbiota characteristics. 3. **The relationship between gut microbiota imbalance and different CLAD stages**: The study examines the changes in the gut microbiota of lung transplant recipients at different CLAD stages to understand whether changes in the gut microbiota are related to the development of CLAD. The main findings of the study include: - The gut microbiota diversity in patients with end-stage lung disease and lung transplant recipients is lower than that in healthy control groups, and this imbalance is exacerbated after lung transplantation. - Different combinations of immunosuppressants and antibiotics are associated with specific gut microbiota characteristics. - At different stages of CLAD, lung transplant recipients exhibit different gut microbiota characteristics, with recipients at CLAD 0 stage being more similar to healthy control groups. In summary, this study reveals the characteristics of gut microbiota changes in patients with end-stage lung disease and lung transplant recipients, and their relationship with drug treatment and CLAD, providing a basis for further exploration of interventions targeting the gut microbiota.